Conjugation News and Research

RSS

Peptide-based vaccine fails to protect mice against SARS-CoV-2 despite T cell response

A recent study observed that peptide-based vaccination against SARS-CoV-2 failed to protect mice against COVID-19, albeit eliciting T cell responses.

28 Feb 2022

Study explores the boosting of SARS-CoV-2 adenovirus vaccine-induced immunity by capsid decoration

Researchers demonstrated that decorating the capsid surface of adenovirus vaccine vectors with a newly discovered protein superglue, DogTag/DogCatcher generates potent SARS-CoV-2-specific humoral and cellular immunity.

24 Feb 2022

Imaging microscopy shows killer T-cells targeting SARS-CoV-2 spike protein

Researchers demonstrate how cytotoxic T-lymphocytes (CTLs) with specificity for SARS-CoV-2 eliminate multiple infected targets.

30 Jan 2022

An assessment of pH-sensitive cationic lipid nanoparticles for drug delivery

A recent review looks at the molecular design of pH-sensitive cationic lipids and their applications for various tissues and cell types.

7 Dec 2021

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.

23 Nov 2021

Enzymes with diverse functions can be rationally harnessed to offer traceless protein synthesis

A multi-enzyme platform is developed for sequence-unconstrained traceless protein synthesis and modification with either synthetic peptides or recombinant proteins, according to a new study out of Chinese Academy of Sciences and Fresenius Kabi.

22 Oct 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants -; $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

New DNA writing technique can precisely and efficiently edit bacterial genomes

Biological engineers at MIT have devised a new way to efficiently edit bacterial genomes and program memories into bacterial cells by rewriting their DNA.

5 Aug 2021

Researchers develop a transferrable and integrative type I CRISPR-based platform to edit superbugs

A research team led by Dr Aixin YAN, Associate Professor from the Research Division for Molecular & Cell Biology, Faculty of Science, in collaboration with Honorary Clinical Professor Patrick CY WOO from the Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, reported the development of a transferrable and integrative type I CRISPR-based platform.

23 Jul 2021

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Researchers in the United States have designed a modular protein subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited a strong immune response in macaques and prevented the animals from developing coronavirus disease 2019 (COVID-19).

15 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

In a recent study published in the journal Science Immunology, scientists have revealed that the presence of CD8+ T cells against conserved epitopes of seasonal coronaviruses is associated with mild coronavirus disease 2019 (COVID-19). These immune cells exhibit a memory phenotype and provide protection against severe disease.

7 Jul 2021

New antibody conjugate delivers drugs to bone tumors and inhibits metastasis

Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it.

23 Jun 2021

LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates

Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc.

From Iksuda Therapeutics 22 Jun 2021

Use of nanotherapeutics in treating coronavirus diseases

Despite advancements in medicine, viral infections still pose a huge threat to human health and are a significant concern for global public health systems.

22 Jun 2021

Iksuda Therapeutics closes $47 million financing round

Iksuda Therapeutics (Iksuda) has announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies.

From Iksuda Therapeutics 8 Jun 2021

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.

7 Jun 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

A new strain of common probiotic can potentially be more effective at protecting infant health

Researchers at the University of Helsinki have created a strain of the Lacticaseibacillus rhamnosus GG probiotic that is able to utilize both lactose and casein as well as reproduce in dairy products.

29 Apr 2021